{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:32:03Z","timestamp":1773790323729,"version":"3.50.1"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1393_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize the patterns, risk factors, and reporting trends of adverse drug reactions (ADRs) in a tertiary care hospital in China to inform targeted medication safety interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1393_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective analysis was conducted on 5,564 ADR reports extracted from the National Adverse Drug Reaction Monitoring System (2019\u20132024). Reports were assessed for causality using the WHO-UMC criteria. Descriptive statistics and chi-squared tests were employed to analyze demographics, reporting trends, causative drugs, administration routes, and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1393_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean patient age was 62.4 years, with males slightly predominating (52.5\u202f%). ADR reporting increased markedly over the study period, with pharmacists becoming the primary reporters (93.1\u202f% in 2024). Intravenous infusion was the most common route (67.3\u202f%). Antineoplastic agents were the predominant drug class implicated (34.2\u202f%), followed by anti-infectives (10.8\u202f%) and cardiovascular drugs (9.4\u202f%). Statistically significant associations were found between ADR outcomes and both the type of ADR (new\/serious vs. general, p&lt;0.001) and the administration route (intravenous vs. oral, p&lt;0.001). No significant association was observed between patient age and ADR outcomes (p=0.244).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1393_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antineoplastic drugs and intravenous administration are key ADR risk factors. Enhanced monitoring of high-risk medications and optimized infusion protocols are needed. Limitations include retrospective single-center design and reporting biases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1393","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:04:34Z","timestamp":1773777874000},"source":"Crossref","is-referenced-by-count":0,"title":["Retrospective analysis of adverse drug reaction patterns from the national monitoring system in a tertiary care hospital in China (2019\u20132024)"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9447-7558","authenticated-orcid":false,"given":"Xiao-Lei","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Pharmacy , Jieshou People\u2019s Hospital , Fuyang , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8696-252X","authenticated-orcid":false,"given":"Xiao-Yu","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Jieshou People\u2019s Hospital , Fuyang , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Jieshou People\u2019s Hospital , Fuyang , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9503-6283","authenticated-orcid":false,"given":"Feng-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Jieshou People\u2019s Hospital , Fuyang , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0132-0137","authenticated-orcid":false,"given":"Qian-Qian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Jieshou People\u2019s Hospital , Fuyang , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5753-3248","authenticated-orcid":false,"given":"Jun-Tao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Jieshou People\u2019s Hospital , Fuyang , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9756-6218","authenticated-orcid":false,"given":"Ya-Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Jieshou People\u2019s Hospital , Fuyang , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026031720042636643_j_med-2026-1393_ref_001","doi-asserted-by":"crossref","unstructured":"Walker, LE, Pirmohamed, M. Increasing trend in hospitalisation due to adverse drug reactions: can we stem the tide? Drug Therapeut Bull 2023;61:87\u201391. https:\/\/doi.org\/10.1136\/dtb.2022.000050.","DOI":"10.1136\/dtb.2022.000050"},{"key":"2026031720042636643_j_med-2026-1393_ref_002","doi-asserted-by":"crossref","unstructured":"Strobach, D, Pudritz, Y, Huttner, D. Retrospective analysis of adverse drug reaction enquiries to a hospital drug information service: lessons to be learned to increase in-hospital drug safety. Int J Pharm Pract 2024;32:384\u201391. https:\/\/doi.org\/10.1093\/ijpp\/riae036.","DOI":"10.1093\/ijpp\/riae036"},{"key":"2026031720042636643_j_med-2026-1393_ref_003","unstructured":"Kose, E, Nakagawa, S, Niki, K, Hashizume, J, Kawazoe, T, Suzuki, N, et al.. Pharmacist interventions for adverse drug reactions in palliative care: a multicentre pilot study. Pharmazie 2023;78:141\u20139. https:\/\/doi.org\/10.1691\/ph.2023.3554."},{"key":"2026031720042636643_j_med-2026-1393_ref_004","doi-asserted-by":"crossref","unstructured":"Cacabelos, R, Naidoo, V, Corzo, L, Cacabelos, N, Carril, JC. Genophenotypic factors and pharmacogenomics in adverse drug reactions. Int J Mol Sci 2021;22:13302. https:\/\/doi.org\/10.3390\/ijms222413302.","DOI":"10.3390\/ijms222413302"},{"key":"2026031720042636643_j_med-2026-1393_ref_005","doi-asserted-by":"crossref","unstructured":"Malki, MA, Pearson, ER. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J 2020;20:355\u201366. https:\/\/doi.org\/10.1038\/s41397-019-0122-0.","DOI":"10.1038\/s41397-019-0122-0"},{"key":"2026031720042636643_j_med-2026-1393_ref_006","doi-asserted-by":"crossref","unstructured":"Aziz, T, Shabbir, MA, Sarwar, A, Khan, AA, Zhao, L, Yang, Z, et al.. Exploring the multifaceted probiotic potential of Lactiplantibacillus plantarum NMGL2, investigating its antimicrobial resistance profiles and bacteriocin production. J\u00a0Microbiol Methods 2025;236:107178. https:\/\/doi.org\/10.1016\/j.mimet.2025.107178.","DOI":"10.1016\/j.mimet.2025.107178"},{"key":"2026031720042636643_j_med-2026-1393_ref_007","doi-asserted-by":"crossref","unstructured":"Aziz, T, Naveed, M, Shabbir, MA, Sarwar, A, Khan, AA, Hasnain, A, et al.. Whole genome analysis of Tibetan kefir-derived Lactiplantibacillus plantarum 12-3 elucidates its genomic architecture, antimicrobial and drug resistance, potential probiotic functionality and safety. Front Biosci (Landmark Ed) 2024;29:147. https:\/\/doi.org\/10.31083\/j.fbl2904147.","DOI":"10.31083\/j.fbl2904147"},{"key":"2026031720042636643_j_med-2026-1393_ref_008","doi-asserted-by":"crossref","unstructured":"Zazzara, MB, Palmer, K, Vetrano, DL, Carf\u00ec, A, Onder, G. Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med 2021;12:463\u201373. https:\/\/doi.org\/10.1007\/s41999-021-00481-9.","DOI":"10.1007\/s41999-021-00481-9"},{"key":"2026031720042636643_j_med-2026-1393_ref_009","doi-asserted-by":"crossref","unstructured":"Lu, Y, Zhou, L, Zou, Y, Wei, H, Zhou, Y, Guo, X, et al.. Antibiotic-induced severe cutaneous adverse reactions: a single-center retrospective study over ten years. Front Immunol 2024;15:1415830. https:\/\/doi.org\/10.3389\/fimmu.2024.1415830.","DOI":"10.3389\/fimmu.2024.1415830"},{"key":"2026031720042636643_j_med-2026-1393_ref_010","doi-asserted-by":"crossref","unstructured":"Monteiro, C, Duarte, AP, Alves, G. Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system. Expet Opin Drug Saf 2021;20:109\u201318. https:\/\/doi.org\/10.1080\/14740338.2020.1849137.","DOI":"10.1080\/14740338.2020.1849137"},{"key":"2026031720042636643_j_med-2026-1393_ref_011","doi-asserted-by":"crossref","unstructured":"Hoel, RW, Giddings Connolly, RM, Takahashi, PY. Polypharmacy management in older patients. Mayo Clin Proc 2021;96:242\u201356. https:\/\/doi.org\/10.1016\/j.mayocp.2020.06.012.","DOI":"10.1016\/j.mayocp.2020.06.012"},{"key":"2026031720042636643_j_med-2026-1393_ref_012","doi-asserted-by":"crossref","unstructured":"Karri, K, Yarra, P. Learn, recognise and prevent adverse drug reactions\/events in elderly hospitalised patients. Evid Base Nurs 2022;25:87. https:\/\/doi.org\/10.1136\/ebnurs-2020-103374.","DOI":"10.1136\/ebnurs-2020-103374"},{"key":"2026031720042636643_j_med-2026-1393_ref_013","doi-asserted-by":"crossref","unstructured":"Heck, J, Noltemeyer, N, Schulze Westhoff, M, Deest-Gaubatz, S, Schr\u00f6der, S, Krichevsky, B, et al.. Adverse drug reactions in geriatric psychiatry-retrospective cohort study of a 6-year period. Ir J Med Sci 2023;192:2917\u201327. https:\/\/doi.org\/10.1007\/s11845-023-03300-1.","DOI":"10.1007\/s11845-023-03300-1"},{"key":"2026031720042636643_j_med-2026-1393_ref_014","doi-asserted-by":"crossref","unstructured":"Insani, WN, Whittlesea, C, Wei, L. Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: a cross-sectional study. PLoS One 2024;19:e0307237. https:\/\/doi.org\/10.1371\/journal.pone.0307237.","DOI":"10.1371\/journal.pone.0307237"},{"key":"2026031720042636643_j_med-2026-1393_ref_015","doi-asserted-by":"crossref","unstructured":"Zhou, F, Yang, Y, Zhang, L, Cheng, Y, Han, B, Lu, Y, et al.. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors. ESMO Open 2023;8:101560. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101560.","DOI":"10.1016\/j.esmoop.2023.101560"},{"key":"2026031720042636643_j_med-2026-1393_ref_016","doi-asserted-by":"crossref","unstructured":"Jimenez-Rodriguez, TW, de Las Vecillas, L, Labella, M, Lynch, DM, Besz, KM, Marquis, K, et al.. Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes, and management with desensitization. Allergy 2024;79:679\u201389. https:\/\/doi.org\/10.1111\/all.15940.","DOI":"10.1111\/all.15940"},{"key":"2026031720042636643_j_med-2026-1393_ref_017","doi-asserted-by":"crossref","unstructured":"Muraro, E, Fanetti, G, Lupato, V, Giacomarra, V, Steffan, A, Gobitti, C, et al.. Cetuximab in locally advanced head and neck squamous cell carcinoma: biological mechanisms involved in efficacy, toxicity and resistance. Crit Rev Oncol Hematol 2021;164:103424. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103424.","DOI":"10.1016\/j.critrevonc.2021.103424"},{"key":"2026031720042636643_j_med-2026-1393_ref_018","doi-asserted-by":"crossref","unstructured":"Jin, Z, Zhao-Xia, L, Fan-Ke, P, Wen-Juan, Z, Min-Li, W, Han-Yi, Z. Progress in the study of reproductive toxicity of platinum-based antitumor drugs and their means of prevention. Front Pharmacol 2024;15:1327502. https:\/\/doi.org\/10.3389\/fphar.2024.1327502.","DOI":"10.3389\/fphar.2024.1327502"},{"key":"2026031720042636643_j_med-2026-1393_ref_019","doi-asserted-by":"crossref","unstructured":"Onita, T, Ishihara, N, Yano, T. PK\/PD-Guided strategies for appropriate antibiotic use in the era of antimicrobial resistance. Antibiotics (Basel) 2025;14:92. https:\/\/doi.org\/10.3390\/antibiotics14010092.","DOI":"10.3390\/antibiotics14010092"},{"key":"2026031720042636643_j_med-2026-1393_ref_020","doi-asserted-by":"crossref","unstructured":"Lacroix, C, Pietri, T, Montero, V, Soeiro, T, Rouby, F, Blin, O, et al.. Antibiotic-induced neurological adverse drug reactions. Therapie 2024;79:181\u20138. https:\/\/doi.org\/10.1016\/j.therap.2023.09.008.","DOI":"10.1016\/j.therap.2023.09.008"},{"key":"2026031720042636643_j_med-2026-1393_ref_021","doi-asserted-by":"crossref","unstructured":"Alvarez-Arango, S, Ogunwole, SM, Sequist, TD, Burk, CM, Blumenthal, KG. Vancomycin infusion reaction\u00a0\u2013\u00a0moving beyond \u201cred man syndrome\u201d. N\u00a0Engl J Med 2021;384:1283\u20136. https:\/\/doi.org\/10.1056\/NEJMp2031891.","DOI":"10.1056\/NEJMp2031891"},{"key":"2026031720042636643_j_med-2026-1393_ref_022","doi-asserted-by":"crossref","unstructured":"Kuitunen, S, Niittynen, I, Airaksinen, M, Holmstr\u00f6m, AR. Systemic causes of in-hospital intravenous medication errors: a systematic review. J\u00a0Patient Saf 2021;17:e1660\u20138. https:\/\/doi.org\/10.1097\/PTS.0000000000000632.","DOI":"10.1097\/PTS.0000000000000632"},{"key":"2026031720042636643_j_med-2026-1393_ref_023","doi-asserted-by":"crossref","unstructured":"DeFrancesco, CJ, Reichel, JF, Gbaje, E, Popovic, M, Freeman, C, Wong, M, et al.. Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial. Br J Anaesth 2023;130:234\u201341. https:\/\/doi.org\/10.1016\/j.bja.2022.11.003.","DOI":"10.1016\/j.bja.2023.04.032"},{"key":"2026031720042636643_j_med-2026-1393_ref_024","doi-asserted-by":"crossref","unstructured":"Muzaffar, AF, Abdul-Massih, S, Stevenson, JM, Alvarez-Arango, S. Use of the electronic health record for monitoring adverse drug reactions. Curr Allergy Asthma Rep 2023;23:417\u201326. https:\/\/doi.org\/10.1007\/s11882-023-01087-w.","DOI":"10.1007\/s11882-023-01087-w"},{"key":"2026031720042636643_j_med-2026-1393_ref_025","doi-asserted-by":"crossref","unstructured":"Bresso, E, Monnin, P, Bousquet, C, Calvier, FE, Ndiaye, NC, Petitpain, N, et al.. Investigating ADR mechanisms with explainable AI: a feasibility study with knowledge graph mining. BMC Med Inf Decis Making 2021;21:171. https:\/\/doi.org\/10.1186\/s12911-021-01518-6.","DOI":"10.1186\/s12911-021-01518-6"},{"key":"2026031720042636643_j_med-2026-1393_ref_026","doi-asserted-by":"crossref","unstructured":"Ma, C, Wolfinger, RD. Toward an explainable large language model for the automatic identification of the drug-induced liver injury literature. Chem Res Toxicol 2024;37:1524\u201334. https:\/\/doi.org\/10.1021\/acs.chemrestox.4c00134.","DOI":"10.1021\/acs.chemrestox.4c00134"},{"key":"2026031720042636643_j_med-2026-1393_ref_027","doi-asserted-by":"crossref","unstructured":"Knisely, BM, Hatim, Q, Vaughn-Cooke, M. Utilizing deep learning for detecting adverse drug events in structured and unstructured regulatory drug data sets. Pharm Med (Lond) 2022;36:307\u201317. https:\/\/doi.org\/10.1007\/s40290-022-00434-y.","DOI":"10.1007\/s40290-022-00434-y"},{"key":"2026031720042636643_j_med-2026-1393_ref_028","doi-asserted-by":"crossref","unstructured":"Gao, Z, Yang, Y, Meng, R, Yu, J, Zhou, L. Automatic assessment of adverse drug reaction reports with interactive visual exploration. Sci Rep 2022;12:6777. https:\/\/doi.org\/10.1038\/s41598-022-10887-5.","DOI":"10.1038\/s41598-022-10887-5"},{"key":"2026031720042636643_j_med-2026-1393_ref_029","doi-asserted-by":"crossref","unstructured":"Nezu, M, Sakuma, M, Nakamura, T, Sonoyama, T, Matsumoto, C, Takeuchi, J, et al.. Monitoring for adverse drug events of high-risk medications with a computerized clinical decision support system: a prospective cohort study. Int J Qual Health Care 2023;35:mzad095. https:\/\/doi.org\/10.1093\/intqhc\/mzad095.","DOI":"10.1093\/intqhc\/mzad095"},{"key":"2026031720042636643_j_med-2026-1393_ref_030","doi-asserted-by":"crossref","unstructured":"Madhushika, MT, Weerarathna, TP, Liyanage, PLGC, Jayasinghe, SS. Evolution of adverse drug reactions reporting systems: paper based to software based. Eur J Clin Pharmacol 2022;78:1385\u201390. https:\/\/doi.org\/10.1007\/s00228-022-03358-3.","DOI":"10.1007\/s00228-022-03358-3"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1393\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1393\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:04:44Z","timestamp":1773777884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1393\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1393"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1393","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261393"}}